Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Mining, quarrying, and oil and gas extraction tags : Treatment save search
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
Published: 2024-01-03 (Crawled : 12:00) - xortx.com
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 6.59%
H: 27.08%
C: 6.18%
disease kidney treatment
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-05 (Crawled : 12:20) - globenewswire.com
PRTG | $0.28 16.67% 14.29% 280K
|
Mining, Quarrying, and Oil and ...
|
| O: 2.47%
H: 17.65%
C: 0.8%
lung melanoma biotech cancer cell treatment meeting trial
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma – Yahoo Finance
Published: 2023-01-05 (Crawled : 13:20) - spacfeed.com
LTUM | News | $0.0364 33.16% 230K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 0.21%
C: -4.76%
aum302 treatment fda rare designation disease
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tra...
Published: 2022-12-02 (Crawled : 13:00) - biospace.com/
WDH | $1.225 -0.41% -0.41% 360K
|
Finance and Insurance
|
| O: -3.09%
H: 6.37%
C: 2.55%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: -0.55%
H: 0.64%
C: 0.09%
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: -1.49%
H: 3.84%
C: -2.44%
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: -0.16%
H: 1.12%
C: 0.32%
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: -2.22%
H: 9.27%
C: 7.69%
ACET | $1.95 -3.7% -3.85% 730K
|
Health Technology
|
| O: -1.13%
H: 5.01%
C: 4.84%
jelmyto treatment trial response
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
Published: 2021-08-05 (Crawled : 12:00) - globenewswire.com
PRTG | $0.28 16.67% 14.29% 280K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.25%
H: 13.6%
C: 12.88%
treatment lung cancer cancer biotech iot
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
Published: 2021-04-08 (Crawled : 15:00) - biospace.com/
PRTG | $0.28 16.67% 14.29% 280K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 2.26%
C: -3.87%
treatment solid tumors positive biotech iot
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.